Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM012
MIFTS: 53

Pulmonary Sarcoidosis

Categories: Immune diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Sarcoidosis

About this section

MalaCards integrated aliases for Pulmonary Sarcoidosis:

Name: Pulmonary Sarcoidosis 12 15 37
Sarcoidosis, Pulmonary 73 44 70
Sarcoidosis Pulmonary 54
Lung Sarcoidosis 12

Classifications:

MalaCards categories:
Anatomical: Immune diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:13406
MeSH 44 D017565
NCIt 50 C34997
SNOMED-CT 67 187230004
ICD10 32 D86.0 D86.2
UMLS 70 C0036205
Sources

Summaries for Pulmonary Sarcoidosis

About this section
Disease Ontology : 12 A sarcoidosis that is characterized by noncaseating granulomatous infiltration of the lungs and supporting lymph nodes, bilateral hilar adenopathy, and pulmonary issues, has symptom shortness of breath, fatigue, wheezing, and chronic cough, and develops from a type IV hypersensitivity reaction.

MalaCards based summary : Pulmonary Sarcoidosis, also known as sarcoidosis, pulmonary, is related to erythema nodosum and cardiac sarcoidosis, and has symptoms including shortness of breath An important gene associated with Pulmonary Sarcoidosis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and placenta, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as... more...

Sources

Related Diseases for Pulmonary Sarcoidosis

About this section

Diseases related to Pulmonary Sarcoidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 erythema nodosum 30.7 TNF IFNG ICAM1 CSF2
2 cardiac sarcoidosis 30.7 TNF IFNG ACE
3 spondylitis 30.5 TNF IFNG CCR6
4 bronchiolitis obliterans 30.4 TNF SFTPD IFNG CXCR3
5 chronic beryllium disease 30.4 TNF IFNG
6 progressive multifocal leukoencephalopathy 30.2 TNF IL2 CCR6
7 lymphopenia 30.2 ITGAL IL2RA IL2 IFNG
8 osteomyelitis 30.2 TNF IFNG CCL2
9 skin sarcoidosis 30.2 TNF IL2 IFNG ACE
10 cellulitis 30.1 TNF CSF2 CCR6
11 septic arthritis 30.1 TNF IFNG CXCR3
12 tonsillitis 30.1 TNF IL2 IFNG
13 glomerulonephritis 30.1 ITGAL ICAM1 CCL2 ACE
14 histiocytosis 30.1 TNF IFNG CSF2 CCR6
15 cryptococcosis 30.0 TNF IFNG CSF2 CCR6
16 thyroiditis 30.0 TNF IL2 IFNG
17 psoriatic arthritis 30.0 TNF IL2 IFNG CCL2
18 toxoplasmosis 29.9 TNF IFNG CCR5 CCL3
19 meningoencephalitis 29.9 TNF CCR6 CCL5
20 cryptococcal meningitis 29.9 IFNG CSF2 CCR6
21 uveoparotid fever 29.9 TNF IFNG ACE
22 miliary tuberculosis 29.9 TNF IL12RB1 IFNG
23 chronic granulomatous disease 29.9 TNF IL18 IFNG ICAM1 CSF2
24 invasive aspergillosis 29.9 SFTPD IFNG CCR6
25 uveitis 29.9 TNF IL2RA IL2 IFNG ICAM1 CXCR3
26 pericarditis 29.8 TNF IFNG ACE
27 retinal vein occlusion 29.8 TNF CCL2 ACE
28 idiopathic interstitial pneumonia 29.8 SFTPD IFNG ICAM1 CCL2
29 nephrosclerosis 29.8 TNF CCL2 ACE
30 iritis 29.8 TNF CCR6 ACE
31 purpura 29.8 TNF IFNG ACE
32 cutaneous leishmaniasis 29.8 TNF IL2 IFNG CCL2
33 panuveitis 29.8 TNF CCR6 ACE
34 bacterial pneumonia 29.7 TNF SFTPD CCR6 CCL3
35 candidiasis 29.7 TNF IL2 IFNG CSF2
36 pulmonary alveolar proteinosis 29.7 TNF SFTPD CSF2 CCL2
37 crohn's colitis 29.7 TNF IL2 IFNG CCR6
38 ulcerative colitis 29.7 TNF IL2 IFNG ICAM1 CCR6
39 respiratory failure 29.7 TNF SFTPD ICAM1 CCR6 CCL5 CCL2
40 vitiligo-associated multiple autoimmune disease susceptibility 1 29.7 TNF IL2 CCR6
41 macular retinal edema 29.7 TNF ICAM1 CCL2 ACE
42 crescentic glomerulonephritis 29.7 IL2RA ICAM1 CCR5 CCL3 CCL2
43 nocardiosis 29.7 TNF IL12RB1 IFNG
44 keratoconjunctivitis 29.6 TNF IL2 IFNG ICAM1 CCL5 CCL2
45 proteasome-associated autoinflammatory syndrome 1 29.6 TNF IL18 IFNG ICAM1 CCL5 CCL3
46 herpes zoster 29.6 TNF IL2 IFNG CCR6 CCR5
47 silicosis 29.5 TNF SFTPD IL18 CCL2 ACE
48 pneumonia 29.5 TNF SFTPD IFNG CXCL5 CCL5 CCL3
49 posterior uveitis 29.5 TNF IL2RA IL2 IFNG CCR6
50 pleurisy 29.4 TNF IL2 IFNG ICAM1 CCL3 CCL2

Graphical network of the top 20 diseases related to Pulmonary Sarcoidosis:



Diseases related to Pulmonary Sarcoidosis
Sources

Symptoms & Phenotypes for Pulmonary Sarcoidosis

About this section

Symptoms:

12
  • • shortness of breath

GenomeRNAi Phenotypes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.8 CXCR3 ITGAL
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.8 CCL5
3 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.8 CCL5
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.8 ITGAL
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.8 ITGAL
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.8 IL12RB1 ITGAL
7 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.8 CXCR3 ITGAL
8 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.8 ITGAL
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.8 IL12RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.8 IL12RB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.8 ITGAL
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.8 IL12RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.8 CXCR3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.8 ITGAL
15 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.8 ITGAL
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.8 ITGAL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.8 IL12RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.8 ITGAL
19 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.8 CCL5
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.8 CCL5
21 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.8 IL12RB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.8 ITGAL
23 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.8 CCL5 CXCR3 ITGAL
24 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.8 CCL5
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 CXCR3

MGI Mouse Phenotypes related to Pulmonary Sarcoidosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 ACE CCL5 CCR5 CCR6 CSF2 CXCR3
2 homeostasis/metabolism MP:0005376 10.1 ACE CCR5 CCR6 CSF2 CXCR3 ICAM1
3 immune system MP:0005387 10.06 ACE CCL2 CCL5 CCR5 CCR6 CSF2
4 neoplasm MP:0002006 9.61 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
5 respiratory system MP:0005388 9.23 CCR5 CSF2 CXCR3 IFNG IL2 IL2RA
Sources

Drugs & Therapeutics for Pulmonary Sarcoidosis

About this section

Drugs for Pulmonary Sarcoidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
10
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
11
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
12
Nicotine Approved Phase 4 54-11-5 942 89594
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15 Analgesics, Non-Narcotic Phase 4
16 Analgesics Phase 4
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4
18 Immunosuppressive Agents Phase 4
19 Gastrointestinal Agents Phase 4
20 Neuroprotective Agents Phase 4
21 glucocorticoids Phase 4
22 Antiemetics Phase 4
23 Methylprednisolone Acetate Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Protective Agents Phase 4
27 Antirheumatic Agents Phase 4
28 Immunologic Factors Phase 4
29 Antimetabolites Phase 4
30 Vitamin B9 Phase 4
31 Folic Acid Antagonists Phase 4
32 Vitamin B Complex Phase 4
33 Dermatologic Agents Phase 4
34 Folate Phase 4
35 Hormone Antagonists Phase 4
36 Hormones Phase 4
37 Adrenocorticotropic Hormone Phase 4
38 Melanocyte-Stimulating Hormones Phase 4
39 beta-Endorphin Phase 4
40 Neurotransmitter Agents Phase 4
41 Central Nervous System Stimulants Phase 4
42 Cholinergic Agents Phase 4
43 Nicotinic Agonists Phase 4
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
46
Hydroxychloroquine Approved Phase 3 118-42-3 3652
47
Mycophenolic acid Approved Phase 3 24280-93-1 446541
48
Methionine Approved, Nutraceutical Phase 2, Phase 3 63-68-3 6137
49 Carbon-11 methionine Phase 2, Phase 3
50 Antimalarials Phase 3

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
2 Pirfenidone for Progressive Fibrotic Sarcoidosis Unknown status NCT03260556 Phase 4 Pirfenidone;Placebos
3 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
4 The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled Trial Recruiting NCT04314193 Phase 4 Methotrexate;Prednisolone
5 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis Active, not recruiting NCT03320070 Phase 4 Acthar Gel;Placebo
6 Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors Suspended NCT00701207 Phase 4 nicotine patch
7 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
8 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
9 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
10 Mycophenolate for Pulmonary Sarcoidosis Terminated NCT00262132 Phase 3 Mycophenolate
11 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study Unknown status NCT02265874 Phase 1, Phase 2 Habitrol;Placebo to Habitrol
12 A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis Completed NCT02888080 Phase 2 ACZ885;Placebo
13 Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open- Completed NCT00855205 Phase 2 Rituximab
14 Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT00279708 Phase 2 Atorvastatin
15 A Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary Sarcoidosis Completed NCT04020380 Phase 2 Azithromycin 250Mg Capsule
16 Treatment of Pulmonary Sarcoidosis With Pentoxifylline Completed NCT00001877 Phase 2 Pentoxifylline
17 Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial Completed NCT02024555 Phase 2 Levofloxacin;Ethambutol;Azithromycin;Rifampin;Placebo
18 A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Recruiting NCT04064242 Phase 2 CMK389;Placebo
19 A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study Recruiting NCT03727451 Phase 2
20 A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis Active, not recruiting NCT03824392 Phase 1, Phase 2
21 A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS Terminated NCT01732211 Phase 2
22 A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis Terminated NCT00926627 Phase 2 bosentan;placebo
23 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Completed NCT01169038 Phase 1 levaquin; ethambutol; rifampin and azithromycin.
24 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Recruiting NCT03793439 Phase 1 Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Corticosteroid;Tofacitinib 5mg [Xeljanz] 1 year open-label extension
25 A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis Terminated NCT01440192 Phase 1
26 Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study Unknown status NCT01384123
27 SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis Unknown status NCT03140644
28 The Role of Non-pharmacological Rehabilitation Within Pulmonary Sarcoidosis: The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis Completed NCT03336736
29 A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis Completed NCT03324503 Glucocorticoid (prednisone or prednisolone)
30 The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis Completed NCT01587001 Placebo
31 Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis Completed NCT00828828
32 The Effect of Pectoralis Muscle Strength on Pulmonary Function in Elderly With Interstitial Lung Disease Completed NCT04803617
33 The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants Completed NCT00512967
34 Feasibility & Effect of a Tele-rehabilitation Program in Pulmonary Sarcoidosis Recruiting NCT03914027
35 Non-invasive Profiling of Breath Volatile Organic Compounds in Sarcoidosis: Relation to the Lung Microbiome and Markers of Disease Progression. Recruiting NCT04318392
36 The Effect of Inspiratory Muscle Training and Breathing Exercises Combined With Upper Extremity and Trunk in Patients With Sarcoidosis Recruiting NCT04173689
37 CASPA (CArdiac Sarcoidosis in PApworth): Improving the Diagnosis of Cardiac Disease in Patients With Pulmonary Sarcoidosis Recruiting NCT03599414
38 Role of Genetic Factors in the Pathogenesis of Lung Disease Recruiting NCT00001532
39 Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis Recruiting NCT03145922
40 Single-centre Study Exploring the Utility of Hyperpolarized 129Xe Magnetic Resonance Imaging in Healthy Volunteers and Patients With Lung Disease Recruiting NCT03455686
41 Stromal Gene Expression During Pulmonary Sarcoidosis Terminated NCT00837668
42 Pulmonary Rehabilitation in Fibrotic Pulmonary Sarcoidosis (Stage IV): Randomized Controlled Trial Terminated NCT02044939

Search NIH Clinical Center for Pulmonary Sarcoidosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Sarcoidosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pulmonary Sarcoidosis:
PDA001, Placenta-derived cells for pulmonary sarcoidosis
Embryonic/Adult Cultured Cells Related to Pulmonary Sarcoidosis:
Placenta-derived cells PMIDs: 22469567

Cochrane evidence based reviews: sarcoidosis, pulmonary

Sources

Genetic Tests for Pulmonary Sarcoidosis

About this section
Sources

Anatomical Context for Pulmonary Sarcoidosis

About this section

MalaCards organs/tissues related to Pulmonary Sarcoidosis:

40
Lung, T Cells, Placenta, Skin, Monocytes, Lymph Node, Thyroid
Sources

Publications for Pulmonary Sarcoidosis

About this section

Articles related to Pulmonary Sarcoidosis:

(show top 50) (show all 2443)
# Title Authors PMID Year
1
The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. 61 54
20070603 2010
2
CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. 61 54
19679608 2010
3
CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. 54 61
19386686 2009
4
Characteristics of patients presenting with erythema nodosum and sarcoidosis. 54 61
19722355 2009
5
Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. 54 61
19218675 2008
6
CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. 61 54
17550373 2007
7
Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. 54 61
17052298 2006
8
Inflammatory markers in the exhaled breath condensate of patients with pulmonary sarcoidosis. 61 54
17072062 2006
9
Inflammatory cytokine levels in induced sputum and bronchoalveolar lavage fluid in pulmonary sarcoidosis. 61 54
18610674 2006
10
Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. 61 54
16734560 2006
11
Depressed peroxisome proliferator-activated receptor gamma (PPargamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma). 54 61
17937104 2006
12
Long-term use of corticosteroid eye drops delays the spontaneous remission of pulmonary sarcoidosis. 61 54
15109125 2004
13
Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. 61 54
14665489 2003
14
Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis. 54 61
13678433 2003
15
Evaluation of bronchoalveolar lavage fluid phospholipids and cytokine release by alveolar macrophages as prognostic markers in sarcoidosis. 61 54
14512673 2003
16
Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. 61 54
12653850 2003
17
CC and C chemokine expression in pulmonary sarcoidosis. 54 61
12449175 2002
18
CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. 54 61
11803051 2002
19
Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. 61 54
11790661 2002
20
Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-alpha and INF-gamma. 61 54
11817671 2001
21
[Clinical significance of serum KL-6 in pulmonary sarcoidosis]. 61 54
11855079 2001
22
Ultrastructural study of expression of adhesion molecules between blood monocytes and alveolar macrophages from patients with pulmonary sarcoidosis. 61 54
11989775 2001
23
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. 61 54
11390417 2001
24
IL-18 might reflect disease activity in mild and moderate asthma exacerbation. 54 61
11174201 2001
25
Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. 61 54
11208635 2001
26
KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. 61 54
11694811 2001
27
IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. 54 61
11123348 2001
28
Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. 61 54
11069843 2000
29
Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. 54 61
11091281 2000
30
Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis. 61 54
10899249 2000
31
Possible role of L-selectin in T lymphocyte alveolitis in patients with active pulmonary sarcoidosis. 54 61
10886252 2000
32
CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. 54 61
10806168 2000
33
Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. 61 54
10508796 1999
34
Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis. 54 61
10335007 1999
35
TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. 54 61
10400819 1999
36
Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. 54 61
9927365 1999
37
Immunohistochemical localization of B7 costimulating molecules and major histocompatibility complex class II antigen in pulmonary sarcoidosis. 61 54
10461083 1999
38
Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. 54 61
9834133 1998
39
Chemokines in the bronchoalveolar lavage fluid of patients with sarcoidosis. 61 54
9475238 1997
40
Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. 61 54
9344512 1997
41
Pentoxifylline in treatment of sarcoidosis. 54 61
9154873 1997
42
Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis. 61 54
9042667 1997
43
Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis. 61 54
8893383 1996
44
Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. 54 61
8752945 1996
45
Shared amino acid motifs in T-cell receptor beta junctional regions of bronchoalveolar T cells in patients with pulmonary sarcoidosis. 61 54
8680698 1996
46
Activation of bronchoalveolar lavage T lymphocytes and clinical, functional and radiological features in sarcoidosis. 54 61
8532961 1995
47
[Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis]. 54 61
7615305 1995
48
Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. 54 61
8589268 1995
49
TNF alpha mRNA, but not IL-1 beta, is differentially expressed in lung macrophages of patients with active pulmonary sarcoidosis. 61 54
8036337 1994
50
Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. 54 61
8118632 1994
Sources

Variations for Pulmonary Sarcoidosis

About this section
Sources

Expression for Pulmonary Sarcoidosis

About this section
Search GEO for disease gene expression data for Pulmonary Sarcoidosis.
Sources

Pathways for Pulmonary Sarcoidosis

About this section

Pathways related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.09 TNF ITGAL IL2RA IL2 IL18 IL12RB1
2
ERK Signaling 63
Show member pathways
 13.8 TNF ITGAL IL2RA IL2 IL18 IL12RB1
3
PEDF Induced Signaling 63
Show member pathways
 13.65 TNF IL2RA IL2 IL18 IL12RB1 IFNG
4
TGF-Beta Pathway 63
Show member pathways
 13.62 TNF ITGAL IL2RA IL2 IL18 IL12RB1
5
Integrin Pathway 63
Show member pathways
 13.5 ITGAL ICAM1 CXCR3 CXCL9 CXCL5 CCR6
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 TNF IL2RA IL2 IL18 IL12RB1 IFNG
7
Akt Signaling 63
Show member pathways
 13.34 TNF ITGAL IL2RA IL2 IL18 IL12RB1
8
PAK Pathway 63
Show member pathways
 13.28 TNF IL2RA IL2 IL18 IL12RB1 CXCR3
9
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.27 TNF SFTPD IL2 IL18 IFNG ICAM1
10
Human cytomegalovirus infection 36
Show member pathways
 13.03 TNF ICAM1 CSF2 CCR5 CCL5 CCL3
11
CCR5 Pathway in Macrophages 63
Show member pathways
 12.98 CXCR3 CXCL9 CXCL5 CCR6 CCR5 CCL5
12
Allograft rejection 1 36
Show member pathways
 12.96 TNF ITGAL IL2RA IL2 IFNG ICAM1
13
Measles 36
Show member pathways
 12.91 TNF ITGAL IL2RA IL2 IL18 IFNG
14
Immune response NFAT in immune response 23
Show member pathways
 12.73 TNF IL2RA IL2 IL18 IL12RB1 IFNG
15
Th17 cell differentiation 36
Show member pathways
 12.7 TNF IL2RA IL2 IL18 IL12RB1 IFNG
16
Immune response IL-23 signaling pathway 23
Show member pathways
 12.69 TNF IL2 IL18 IL12RB1 IFNG CXCL9
17
NF-kappaB Signaling 4
12.67 TNF IL2RA IL2 IFNG CCL5 CCL2
18
T cell receptor signaling pathway 36
Show member pathways
 12.66 TNF IL2 IFNG CSF2 CCR5
19
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.63 TNF ITGAL IL2 IFNG ICAM1 CSF2
20
JAK-STAT signaling pathway 36
Show member pathways
 12.5 IL2RA IL2 IL12RB1 IFNG CSF2
21
Human T-cell leukemia virus 1 infection 36
12.47 TNF ITGAL IL2RA IL2 ICAM1 CSF2
22
Folate Metabolism 1
Show member pathways
 12.46 TNF IL2 IFNG ICAM1 CCL5 CCL2
23
Shigellosis 36
12.43 TNF IL18 CSF2 CCL5
24
IL-17 Family Signaling Pathways 64
Show member pathways
 12.43 TNF IFNG CXCL5 CSF2 CCL2
25
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.33 TNF IL2RA IL2 IL18 IFNG
26
Autophagy Pathway 66
12.32 ITGAL IL2RA IL12RB1 CCR5
27
NOD-like receptor signaling pathway 36
12.29 TNF IL18 CCL5 CCL2
28
Fluid shear stress and atherosclerosis 36
12.16 TNF IFNG ICAM1 CCL2
29
Yersinia infection 36
12.15 TNF IL2 IL18 CCL2
30
Spinal Cord Injury 1
12.14 TNF IL2 IFNG ICAM1 CCL2
31
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.11 TNF ITGAL IL2RA IL2 IFNG CSF2
32
IL12-mediated signaling events 1
Show member pathways
 12.09 IL2RA IL2 IL18 IL12RB1 IFNG CCR5
33
TNF signaling pathway 36
12.08 TNF ICAM1 CXCL5 CSF2 CCL5 CCL2
34
Interleukin-4 and 13 signaling 65
12.06 TNF IL18 ICAM1 CCL2
35
Glucocorticoid receptor regulatory network 1
11.91 IL2 IFNG ICAM1 CSF2
36
Th1 Differentiation Pathway 64
Show member pathways
 11.89 TNF IL2 IL18 IL12RB1 IFNG
37
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.88 IL12RB1 ICAM1 CSF2
38
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 TNF IL2RA IL2 IFNG CSF2
39
Dendritic Cells Developmental Lineage Pathway 64
11.86 TNF IL2 IFNG CSF2
40
IgA-Producing B Cells in the Intestine 64
11.82 TNF ITGAL IL2RA ICAM1 CCR6
41
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.79 TNF IL2 IFNG ICAM1 CSF2
42
Lung fibrosis 1
11.78 TNF CSF2 CCL5 CCL3 CCL2
43
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.77 TNF IL2RA IL2 IFNG
44
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 11.74 TNF IL2RA IL2 IL18 CXCR3 CXCL9
45
Innate Lymphoid Cell Differentiation Pathways 64
11.71 TNF IL2RA IL2 IL18 IL12RB1 IFNG
46
MSP-RON Signaling 63
11.65 TNF IL18 IFNG CCL2
47
Malaria 36
11.65 TNF ITGAL IL18 IFNG ICAM1 CCL2
48
Rheumatoid arthritis 36
11.62 TNF ITGAL IL18 IFNG ICAM1 CXCL5
49
Photodynamic therapy-induced AP-1 survival signaling. 1
11.61 TNF IL2 IFNG
50
Aryl Hydrocarbon Receptor Pathway 1
11.58 TNF IL2 IFNG
Sources

GO Terms for Pulmonary Sarcoidosis

About this section

Cellular components related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNF SFTPD IL2 IL18 IFNG CXCL9
2 cell surface GO:0009986 9.8 TNF ITGAL IL2RA ICAM1 CXCR3 CCR6
3 extracellular space GO:0005615 9.77 TNF SFTPD IL2 IL18 IFNG ICAM1
4 external side of plasma membrane GO:0009897 9.28 TNF IL2RA IL12RB1 ICAM1 CXCR3 CXCL9

Biological processes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 ITGAL IL18 IL12RB1 CXCR3 CXCL9 CXCL5
2 G protein-coupled receptor signaling pathway GO:0007186 10.24 IL2 CXCR3 CXCL9 CXCL5 CCR6 CCR5
3 positive regulation of cell proliferation GO:0008284 10.13 IL2 IFNG CXCR3 CXCL5 CSF2
4 positive regulation of gene expression GO:0010628 10.12 TNF IL18 IFNG CSF2 CCL3
5 cell surface receptor signaling pathway GO:0007166 10.06 IL2RA IFNG CXCR3 CCR5 CCL2
6 cell-cell signaling GO:0007267 10.04 IL2 IL18 CXCL9 CXCL5 CCR5 CCL5
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.03 TNF ICAM1 CCL5 CCL3 CCL2
8 MAPK cascade GO:0000165 10.02 TNF IL2RA IL2 IL18 CSF2 CCR5
9 cellular response to lipopolysaccharide GO:0071222 10 TNF ICAM1 CXCL9 CXCL5 CSF2 CCR5
10 inflammatory response GO:0006954 10 TNF ITGAL IL2RA IL18 CXCR3 CXCL9
11 positive regulation of cytosolic calcium ion concentration GO:0007204 9.98 IL2 CXCR3 CCR6 CCR5
12 cellular response to tumor necrosis factor GO:0071356 9.97 ICAM1 CCL5 CCL3 CCL2
13 cellular response to interferon-gamma GO:0071346 9.97 IL12RB1 ICAM1 CCL5 CCL3 CCL2
14 positive regulation of inflammatory response GO:0050729 9.96 TNF IL2 IL18 IFNG CCL3
15 cell chemotaxis GO:0060326 9.95 CXCR3 CXCL5 CCR6 CCR5 CCL5 CCL3
16 calcium-mediated signaling GO:0019722 9.94 CXCR3 CCR6 CCR5 CCL3
17 cellular response to interleukin-1 GO:0071347 9.93 ICAM1 CCL5 CCL3 CCL2
18 neutrophil chemotaxis GO:0030593 9.93 CXCL9 CXCL5 CCL5 CCL3 CCL2
19 cellular response to organic cyclic compound GO:0071407 9.92 TNF IL18 CCL5 CCL3 CCL2
20 chemotaxis GO:0006935 9.92 CXCR3 CXCL9 CXCL5 CCR6 CCR5 CCL5
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 TNF IL18 CCL5
22 positive regulation of interferon-gamma production GO:0032729 9.91 TNF IL2 IL18 IL12RB1
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL2 IL18 IFNG CSF2 CCL5
24 humoral immune response GO:0006959 9.9 TNF IFNG CCR6 CCL2
25 regulation of insulin secretion GO:0050796 9.89 TNF IFNG CCL5
26 positive regulation of T cell proliferation GO:0042102 9.89 IL2RA IL2 CCL5
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF IL18 CCL5
28 positive regulation of interleukin-1 beta production GO:0032731 9.88 TNF IFNG CCL3
29 protein kinase B signaling GO:0043491 9.88 TNF CCL5 CCL3 CCL2
30 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TNF IL18 CCL5 CCL3 CCL2
31 cellular defense response GO:0006968 9.87 CXCL9 CCR6 CCR5
32 positive regulation of phagocytosis GO:0050766 9.86 TNF SFTPD IFNG
33 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IFNG ICAM1
34 monocyte chemotaxis GO:0002548 9.85 CCL5 CCL3 CCL2
35 positive regulation of activated T cell proliferation GO:0042104 9.85 IL2RA IL2 IL18 IL12RB1
36 lymphocyte chemotaxis GO:0048247 9.84 CCL5 CCL3 CCL2
37 leukocyte cell-cell adhesion GO:0007159 9.83 ITGAL ICAM1 CCL5
38 macrophage chemotaxis GO:0048246 9.81 SFTPD CCL5 CCL3 CCL2
39 eosinophil chemotaxis GO:0048245 9.8 CCL5 CCL3 CCL2
40 dendritic cell chemotaxis GO:0002407 9.79 CCR6 CCR5 CCL5
41 regulation of regulatory T cell differentiation GO:0045589 9.79 IL2RA IL2 IFNG
42 chemokine-mediated signaling pathway GO:0070098 9.76 CXCR3 CXCL9 CXCL5 CCR6 CCR5 CCL5
43 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL18
44 response to cholesterol GO:0070723 9.73 CCR5 CCL3
45 T cell chemotaxis GO:0010818 9.73 CXCR3 CCL3
46 negative regulation of amyloid-beta clearance GO:1900222 9.72 TNF IFNG
47 positive regulation of podosome assembly GO:0071803 9.72 TNF CSF2
48 interleukin-2-mediated signaling pathway GO:0038110 9.72 IL2RA IL2
49 signaling GO:0023052 9.71 CCR5 CCL3
50 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.71 CCR5 CCL3

Molecular functions related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 TNF SFTPD ITGAL IL2RA IL2 IL18
2 CCR chemokine receptor binding GO:0048020 9.54 CCL5 CCL3 CCL2
3 C-C chemokine binding GO:0019957 9.5 CXCR3 CCR6 CCR5
4 CCR5 chemokine receptor binding GO:0031730 9.48 CCL5 CCL3
5 phospholipase activator activity GO:0016004 9.46 CCL5 CCL3
6 CCR1 chemokine receptor binding GO:0031726 9.43 CCL5 CCL3
7 C-C chemokine receptor activity GO:0016493 9.43 CXCR3 CCR6 CCR5
8 chemokine activity GO:0008009 9.35 CXCL9 CXCL5 CCL5 CCL3 CCL2
9 chemokine receptor activity GO:0004950 9.33 CXCR3 CCR6 CCR5
10 cytokine activity GO:0005125 9.32 TNF IL2 IL18 IFNG CXCL9 CXCL5
Sources

Sources for Pulmonary Sarcoidosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....